{"filing":{"accession_number":"0001062993-26-005528","cik":"0001997296","ticker":"MDCXW","company_name":"Medicus Pharma Ltd.","form":"8-K","filing_date":"2026-10-23","report_date":"2026-10-20","primary_document":"form8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1997296/000106299326005528/form8k.htm"},"events":[{"id":37697,"run_id":34741,"accession_number":"0001062993-26-005528","anchor_item_number":"3.01","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.94,"summary":"Medicus Pharma received a delisting determination letter from Nasdaq on October 20, 2026, for failure to maintain the $1.00 minimum bid price requirement, but subsequently regained compliance on October 23, 2026. The company faces ongoing delisting risk and cannot assure future compliance with Nasdaq's continued listing standards.","company_name":"Medicus Pharma Ltd.","ticker":"MDCXW","filing_date":"2026-10-23","form":"8-K","submitted_at":null,"items":[{"id":42487,"accession_number":"0001062993-26-005528","item_number":"3.01","item_title":"Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"reasoning":"The filing discloses a delisting determination letter from Nasdaq on October 20, 2026, indicating the Company had failed to regain compliance with the $1.00 minimum bid price requirement and that Nasdaq determined to delist the Company's common shares and warrants from The Nasdaq Capital Market. Although the Company subsequently regained compliance on October 23, 2026 (superseding the delisting determination), the core material event disclosed is the delisting risk and determination. This is a terminal signal affecting the registrant's continued listing status and is highly material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-23T21:16:39.268021+00:00","company_name":"","ticker":null,"filing_date":""},{"id":42488,"accession_number":"0001062993-26-005528","item_number":"8.01","item_title":"Other Events.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.92,"reasoning":"The disclosure describes Medicus Pharma's regained compliance with Nasdaq's Minimum Bid Price Requirement after a period of non-compliance (October 12–23, 2026), with explicit language that \"there can be no assurance that the Company will be able to maintain compliance...in the future.\" This is a delisting-risk event: the company was previously at risk of delisting, has now cured the deficiency, but faces ongoing delisting risk. The materiality is clear—listing status directly affects investor access and valuation.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-23T21:16:39.268021+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":42487,"accession_number":"0001062993-26-005528","item_number":"3.01","item_title":"Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"reasoning":"The filing discloses a delisting determination letter from Nasdaq on October 20, 2026, indicating the Company had failed to regain compliance with the $1.00 minimum bid price requirement and that Nasdaq determined to delist the Company's common shares and warrants from The Nasdaq Capital Market. Although the Company subsequently regained compliance on October 23, 2026 (superseding the delisting determination), the core material event disclosed is the delisting risk and determination. This is a terminal signal affecting the registrant's continued listing status and is highly material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-23T21:16:39.268021+00:00","company_name":"Medicus Pharma Ltd.","ticker":"MDCXW","filing_date":"2026-10-23"},{"id":42488,"accession_number":"0001062993-26-005528","item_number":"8.01","item_title":"Other Events.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.92,"reasoning":"The disclosure describes Medicus Pharma's regained compliance with Nasdaq's Minimum Bid Price Requirement after a period of non-compliance (October 12–23, 2026), with explicit language that \"there can be no assurance that the Company will be able to maintain compliance...in the future.\" This is a delisting-risk event: the company was previously at risk of delisting, has now cured the deficiency, but faces ongoing delisting risk. The materiality is clear—listing status directly affects investor access and valuation.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-23T21:16:39.268021+00:00","company_name":"Medicus Pharma Ltd.","ticker":"MDCXW","filing_date":"2026-10-23"}]}